SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-072008
Filing Date
2022-03-10
Accepted
2022-03-10 16:31:38
Documents
14
Period of Report
2022-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d289285d8k.htm   iXBRL 8-K 25607
2 EX-99.1 d289285dex991.htm EX-99.1 43096
6 GRAPHIC g289285g0308123147739.jpg GRAPHIC 2695
  Complete submission text file 0001193125-22-072008.txt   202509

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20220310.xsd EX-101.SCH 2863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20220310_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20220310_pre.xml EX-101.PRE 11266
8 EXTRACTED XBRL INSTANCE DOCUMENT d289285d8k_htm.xml XML 3359
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 22729499
SIC: 2834 Pharmaceutical Preparations